Menopause is defined by a single clinical milestone: 12 consecutive months without a menstrual period. The average age in the United States is 51, but the range is wide, and everything after that day is called postmenopause. It is not a phase you pass through. It is the rest of your life without ovarian estrogen, and for many women in the Omaha metro, it lasts 30 years or more.
At Midwest Mind & Body Healthcare in Papillion, we provide evidence-based hormone replacement therapy for women navigating that transition and the decades that follow. Many of our patients come in already a few years past their last period. They have been told by a primary-care clinician to "wait it out," or they read the 2002 Women's Health Initiative headlines two decades ago and assumed HRT was off the table forever. Both of those messages are outdated, and the consequences of acting on them, in our experience, are measurable: untreated vasomotor symptoms, thinning vaginal tissue, accelerating bone loss, and a subtle but real decline in quality of life.
Omaha sits inside a strong women's health ecosystem. UNMC, Methodist, CHI Health, and Nebraska Medicine all have robust gynecology and endocrinology departments, but dedicated menopause care, the kind where someone actually sits with you for 45 minutes and talks about the difference between perimenopause and postmenopause, titrates estradiol, and explains the WHI in plain language, remains surprisingly hard to find. Many midlife women end up bouncing between their OB-GYN, their primary care, and internet forums. We built this practice to be a single, unhurried place for that conversation.
Our founder, Kim Wohlwend, MSN, APRN, is dual ANCC board-certified as a Family Nurse Practitioner and Psychiatric-Mental Health Nurse Practitioner. That combination matters in midlife. The symptoms of menopause overlap heavily with thyroid disease, anemia, depression, anxiety, sleep apnea, and medication side effects. A clinician who can only see one slice often treats the wrong thing. We look at the whole picture, write a plan you actually agree with, and follow up closely.
What HRT Treats
Menopause symptoms, in plain language.
Menopause affects far more than hot flashes. Estrogen receptors exist in the brain, blood vessels, bones, skin, bladder, and vaginal tissue. When estrogen drops, all of those systems feel it. HRT, when appropriate, can meaningfully improve most of these areas.
Hot flashes & vasomotor symptoms
Sudden flushes of heat, sweating, and a racing heart that can last 30 seconds to several minutes. Average duration of vasomotor symptoms is 7 to 10 years. Systemic estradiol remains the most effective treatment by a wide margin.
Night sweats & disrupted sleep
The same vasomotor mechanism that drives daytime flushing wakes you at 3 a.m. soaked. Chronic sleep fragmentation drives fatigue, irritability, weight gain, and cognitive complaints. Treating the hot flashes usually fixes the sleep.
GSM, vaginal dryness & painful sex
Genitourinary syndrome of menopause is progressive and does not spontaneously improve. Thinning tissue, dryness, burning, and painful intercourse affect up to 70% of postmenopausal women. Low-dose vaginal estrogen is extremely effective and has minimal systemic absorption.
Urinary symptoms & recurrent UTIs
Estrogen receptors line the urethra and bladder. Postmenopausal women have a documented increase in urinary urgency, stress incontinence, and recurrent urinary tract infections. Local vaginal estrogen reduces UTI recurrence in well-designed trials.
Bone loss & osteoporosis risk
Women can lose up to 20% of bone density in the first 5 to 7 years after menopause. Systemic estrogen is an FDA-approved treatment for prevention of postmenopausal osteoporosis and reduces hip, vertebral, and non-vertebral fractures.
Cognitive changes ("menopause brain")
Word-finding difficulty, short-term memory glitches, and mental fog are real and common. They are not early dementia. Estrogen affects hippocampal function; for many women, systemic HRT started during the early postmenopausal window improves cognitive symptoms.
Mood & anxiety changes
Depression and anxiety can persist or first emerge in postmenopause, often tangled up with sleep loss and vasomotor symptoms. Our dual psychiatric and family NP training lets us treat both hormones and mood. See our mood in midlife page.
Libido & energy changes
Declining testosterone in women contributes to low libido, loss of motivation, and reduced energy. For select patients, low-dose testosterone therapy for women can be added to standard HRT after individualized evaluation.
Is HRT Safe?
Unpacking the WHI, the timing hypothesis, and modern HRT.
Almost every woman who walks into our office has some version of the same question: "I heard hormones cause breast cancer." That sentence has a 23-year history, and it deserves a real answer instead of a shrug.
In July 2002, the estrogen-plus-progestin arm of the Women's Health Initiative (WHI) was stopped early. The news cycle translated a nuanced statistical result into a single scary headline, and HRT prescriptions in the United States fell by roughly 70% within two years. Two decades of reanalysis have reshaped what those results actually mean.
The WHI enrolled women with an average age of 63, more than a decade past menopause for most of them. It used oral conjugated equine estrogens (CEE, Premarin) combined with medroxyprogesterone acetate (MPA, Provera), a synthetic progestin. It did not test transdermal estradiol, it did not test micronized progesterone, and it did not test women in the early postmenopausal window. The absolute risk increases it reported, translated into plain numbers, were small: about 8 more breast cancer cases per 10,000 women per year on combined HRT, and the estrogen-only arm actually showed a non-significant reduction in breast cancer.
Reanalysis by age has been consistent: the timing hypothesis holds up. Women who start systemic HRT before age 60 or within 10 years of menopause show a favorable risk-benefit profile, including reductions in all-cause mortality, fracture, and colorectal cancer. Women who start HRT for the first time in their late 60s or later have different cardiovascular and stroke risk and require a more cautious conversation.
Route matters. Oral estrogen passes through the liver before reaching circulation. That first-pass metabolism increases clotting factors, inflammatory markers, and triglycerides, which is likely why oral formulations carry the venous thromboembolism signal seen in trials. Transdermal estradiol (patch, gel, or spray) bypasses the liver and, in observational data, does not appear to increase VTE or stroke risk to the same degree. For most of our Omaha patients starting HRT, transdermal is our first choice.
Progestogen matters too. Synthetic MPA (the WHI progestin) has been linked in observational studies to a small increase in breast cancer risk when combined with estrogen. Micronized progesterone (Prometrium), which is bioidentical, has a more favorable signal in European observational cohorts and is the progestogen we most often use. A progesterone IUD is another valid option for uterine protection.
Dose matters. We titrate. Starting doses are lower than WHI protocols in most cases, we recheck symptoms at 6 to 12 weeks, and we adjust. Individualized risk assessment, not one-size-fits-all dosing, is how modern HRT is practiced.
Contraindications are real. Systemic estrogen is not appropriate for women with a history of breast cancer, estrogen-sensitive endometrial cancer, active venous thromboembolism, undiagnosed vaginal bleeding, severe active liver disease, or uncontrolled hypertension. We screen carefully. Low-dose vaginal estrogen, because of its minimal systemic absorption, has a broader safety profile and is often reasonable even when systemic HRT is not.
"Why I waited."
One of the most common stories we hear: a woman in her late 50s or 60s who had her last period at 50, powered through 5 to 10 years of hot flashes, gave up on sleep, stopped having sex because intercourse was painful, and believed she was not a candidate for HRT because of something she remembered reading in 2002. Then she reads a 2024 piece in the New York Times or the British Medical Journal, realizes the story has shifted, and books an appointment. We see this story every week. It is usually not too late.
Our Approach
How menopause HRT works here.
Comprehensive evaluation
45-minute first visit covering your menopause timeline, full symptom inventory, medical and family history, current screening status (Pap, mammogram, bone density), cardiovascular and breast cancer risk factors, and what you want from treatment. Labs when indicated.
Individualized HRT plan
We choose route (transdermal vs oral), estrogen dose, progestogen type (micronized oral vs IUD vs not needed if hysterectomy), and whether low-dose vaginal estrogen belongs in the plan for GSM. We also discuss non-hormonal options when HRT is not appropriate.
Long-term management
First follow-up at 6 to 12 weeks to gauge response. Annual reassessment thereafter with blood pressure, symptom review, and updated risk discussion. Mammogram and Pap status confirmed each year. Duration of therapy is not arbitrary, it is a yearly conversation.
Treatment Options
The HRT toolkit, and how we choose.
Hormone replacement therapy is not a single prescription. It is a family of formulations with different routes, doses, and purposes. Part of what a 45-minute visit buys you is the time to talk through why one option fits and another does not.
Systemic estradiol
Estradiol is the bioidentical form of the estrogen your ovaries used to make. It is available in several formulations:
- Transdermal patch (Climara, Vivelle-Dot, generic estradiol patches). Applied once or twice weekly. Most even blood levels. Our first-line choice for most postmenopausal women.
- Transdermal gel (Divigel, Estrogel, Elestrin). Daily application to the arm or thigh. Good option for women who do not tolerate patch adhesive.
- Transdermal spray (Evamist). Daily application, alternative to gel.
- Oral estradiol (Estrace, generic). Once daily. Used selectively when transdermal is not appropriate or preferred. First-pass liver metabolism carries higher VTE risk than transdermal.
Progesterone for uterine protection
If you still have a uterus, unopposed estrogen can cause endometrial hyperplasia and, over time, endometrial cancer. Progesterone prevents this. Options:
- Oral micronized progesterone (Prometrium). Bioidentical, commonly dosed 100 mg nightly (continuous) or 200 mg nightly for 12 days each month (cyclic). Often improves sleep as a bonus.
- Progesterone-releasing IUD (Mirena). Provides uterine protection with minimal systemic progestogen exposure. A good option for women with progesterone side effects or those already needing contraception in early postmenopause.
If you have had a hysterectomy, systemic progesterone is generally not needed, and we use estrogen alone.
Low-dose vaginal estrogen for GSM
This is a separate category and deserves its own conversation. Vaginal estrogen is not the same as systemic HRT. It treats local tissue, with minimal systemic absorption, and is appropriate for almost every postmenopausal woman with vaginal dryness, burning, painful sex, or recurrent UTIs, even many who cannot take systemic HRT.
- Vaginal estradiol cream, tablet, or ring (Estrace cream, Vagifem/Yuvafem, Estring). Applied two to three times per week after an initial loading phase.
- Systemic estrogen levels stay within postmenopausal range on standard vaginal doses.
- Learn more on our vaginal estrogen page.
Non-hormonal options
When HRT is not appropriate or not desired, evidence-based alternatives for vasomotor symptoms include:
- SSRIs/SNRIs (paroxetine 7.5 mg, venlafaxine, escitalopram). FDA-approved low-dose paroxetine (Brisdelle) is labeled for hot flashes.
- Gabapentin, especially useful when night sweats are the dominant symptom.
- Fezolinetant (Veozah), a newer non-hormonal option targeting the NK3 pathway in the hypothalamus.
- Cognitive behavioral therapy for hot flashes and insomnia, with good supporting data.
How long can I stay on HRT?
This is the question everyone asks. The Menopause Society (formerly NAMS) explicitly does not set an arbitrary stop date. Duration is individualized. Many women stay on HRT for 5 to 10 years; some stay longer when symptoms or bone protection justify it. What we do every year is reassess: are you still benefiting, have your risk factors changed, has your screening stayed current, and do you want to continue? Stopping and restarting is possible if symptoms recur, though doing so in your 70s after a long break carries different risks than continuing.
If weight has changed meaningfully during the transition, our medical weight loss program can be integrated with HRT care in the same practice.
Pricing
Transparent self-pay pricing.
Initial Visit
- Full menopause history, symptom inventory, and risk evaluation
- Review of prior labs, screening, imaging
- Labs ordered as clinically indicated
- Individualized HRT plan, or non-hormonal plan if preferred
- Prescriptions sent the same day when appropriate
Follow-Up
- Symptom response check, titration, and dose adjustment
- Annual reassessment and screening review
- Prescription refills
- Secure portal messaging between visits
- No subscription. No hidden fees.
Hormone therapy is self-pay at this practice. A good-faith estimate is available on request. Medication costs are separate and depend on your pharmacy; most generic estradiol patches and oral progesterone are inexpensive with standard prescription discount cards.
Menopause care for the Omaha metro, and beyond.
In-person appointments are offered at our Papillion, Nebraska office, with patients coming from across the Omaha metro and western Iowa. Telehealth is available in 16 states, which lets us continue caring for patients who winter south or have family in other states.
FAQ
Menopause HRT questions.
Is HRT safe after 60?
For most healthy women who started HRT within 10 years of menopause, continuing past 60 is reasonable after an individualized risk discussion. Starting systemic HRT for the first time after 60 carries a different risk profile, particularly for cardiovascular events and stroke, and we evaluate carefully before initiating. Transdermal estradiol and low-dose vaginal estrogen are often preferred in this age group.
What about the WHI study risks?
The 2002 Women's Health Initiative results were widely misinterpreted. The study enrolled women at an average age of 63, used oral conjugated equine estrogens with synthetic medroxyprogesterone acetate, and reported absolute risks that were small in magnitude. Reanalysis by age shows women under 60 or within 10 years of menopause had a favorable risk-benefit profile. Modern HRT typically uses transdermal estradiol and micronized progesterone, which have different safety profiles than the WHI formulations.
Can I still start HRT if I am 10 years past menopause?
The timing hypothesis suggests HRT is safest when started within 10 years of menopause or before age 60. After that window, starting systemic HRT is not categorically off the table, but the risk discussion is more nuanced. Low-dose vaginal estrogen for genitourinary symptoms remains safe at essentially any age, because systemic absorption is minimal. This is a conversation worth having rather than a blanket no.
Do I need a Pap or mammogram to start HRT?
Yes. We expect patients to be current on age-appropriate cervical and breast cancer screening before starting systemic HRT. A mammogram within the past 12 months is standard. We do not perform mammograms in office, but we can help coordinate with UNMC, Methodist, CHI Health, or your primary care provider in the Omaha area.
How long can I stay on hormone therapy?
There is no mandatory stop date. Current Menopause Society guidelines do not set an arbitrary duration limit. Duration is individualized based on symptom burden, bone health, cardiovascular risk, breast cancer risk, and personal preference. Many women stay on HRT for 5 to 10 years or longer. We reassess at every annual visit.
Do I need progesterone if I have had a hysterectomy?
If your uterus has been removed, systemic progesterone is generally not required, and estrogen-only HRT is appropriate. The purpose of progesterone is to protect the uterine lining from unopposed estrogen. Without a uterus, that indication is gone. There are occasional exceptions (some cases of endometriosis or a history of certain cancers), which we discuss individually.
What is the difference between oral and patch estrogen?
Oral estrogen undergoes first-pass liver metabolism, which raises clotting factors and triglycerides. Transdermal estradiol (patch, gel, or spray) bypasses the liver and has lower risk of venous thromboembolism and stroke in observational data. For many women, especially those over 50 or with cardiovascular or clotting risk factors, transdermal is preferred.
Can I get hormone therapy by telehealth in Nebraska?
Yes. Menopause HRT is available by secure telehealth across 16 states, including Nebraska, Iowa, Kansas, Colorado, and Illinois. In-person visits are available at our Papillion office. Labs and blood-pressure checks are coordinated near you through local labs and your primary care provider when appropriate.
It is not too late to feel like yourself.
Evidence-based menopause hormone replacement therapy from a dual ANCC board-certified nurse practitioner. Transparent pricing. In person in Papillion or telehealth across 16 states, including all of Nebraska and the greater Omaha metro.
Book an Appointment